Clinical trials: tuberculosis
Tuberculosis, Pleural Effusion
Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion
Tubercular pleural effusion is the second most common form of extrapulmonary tuberculosis (EPTB) seen in clinical practice after tuberculosis (TB) lymphadenitis.
- Trial name
- NCT01560078
- Where
- India
- Volunteers
- 360 people
- Sponsor
- All India Institute of Medical Sciences
Cystic Fibrosis, Bronchiectasis Adult
Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.
- Conditions
- Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
- Trial name
- NCT04884308
- Testing
- BCG TICE Vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Mycobacterium Infections, Nontuberculous
A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections
The study aims to address the following aims 1. To provide an overview of the epidemiology of the patients who are managed in the Singapore General Hospital for NTM infections. 2.
- Trial name
- NCT02355015
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Tuberculosis
Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
This study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active…
- Trial name
- NCT04975737
- Testing
- GamTBvac
- Where
- Russia
- Volunteers
- 9,500 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Human Immunodeficiency Virus
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
The purpose of this study is to assess the safety and immunogenicity of M72/AS01E vaccination in virally suppressed, antiretroviral-treated participants with human immunodeficiency virus infection (HIV).
- Trial name
- MESA-TB (NCT04556981)
- Testing
- M72/AS01E Mycobacterium tuberculosis vaccine
- Where
- 6 sites in South Africa
- Volunteers
- 402 people
- Sponsor
- Gates Medical Research Institute
Tuberculosis
Clinical Presentation, and Treatment Outcomes in Tuberculous Patients in Sohag Governorate
Tuberculosis (TB) is an infectious disease that commonly affects the lung and is caused by a bacterium called Mycobacterium Tuberculosis.
- Trial name
- NCT06141148
- Testing
- sputum analysis, lymph node biobsy
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
HIV Infections, Tuberculosis
Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients are at an increased risk of contracting malaria.
- Trial name
- NCT00620438
- Testing
- Lumefantrine-artemether and nevirapine, lumefantrine-artemether and efavirenz, Lumefantrine-artemether and rifampicin
- Where
- Uganda
- Volunteers
- 90 people
- Sponsor
- Makerere University
To Compare the Serum Apoptosis-associated Markers Between Patients With Active TB and Patients With LTBI, To Evaluate the Efficiency of Apoptosis-associated Markers to Differentiate Potential of Active TB From LTBI
The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis
To compare the serum apoptosis-associated markers between patients with active TB and patients with LTBI To evaluate the efficiency of apoptosis-associated markers to differentiate potential of active TB from LTBI
- Trial name
- NCT01676155
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Tuberculosis, Pulmonary
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung…
- Trial name
- NCT07077213
- Testing
- 18F-FAPI-74
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Tuberculosis
Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)
Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB meningitis and drug resistant TB, among…
- Trial name
- NCT03559582
- Volunteers
- 478 people
- Sponsor
- University of Virginia
Drug Resistant Tuberculosis
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB…
- Trial name
- NCT05671718
- Testing
- Nurse-Led Treatment in Primary Care
- Where
- 5 sites in South Africa
- Volunteers
- 2,944 people
- Sponsor
- Johns Hopkins University
Tuberculosis (TB), Tuberculosis Vaccines
Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region
This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region.
- Trial name
- NCT00600782
- Testing
- GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)
- Where
- South Africa
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Leprosy
Effect of Weight and/or Obesity on Dapsone Drug Concentrations
This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
- Conditions
- Obesity, Leprosy, Tuberculosis
- Trial name
- NCT01165840
- Testing
- Dapsone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
HIV Infections, Hepatitis B
Health and Migration Trajectories of Housekeepers in Bamako
In Mali, migration from rural zones is a cultural phenomenon existing since 1970. During the dry season (9 months), an important number of young women leave their villages and migrate towards urban zones to seek for a job.
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C, Tuberculosis
- Trial name
- 2DM2K (NCT05472051)
- Testing
- Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO
- Where
- Mali
- Volunteers
- 644 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV/AIDS, Tuberculosis
Pharmacokinetics of Atazanavir in Special Populations
The lack of data relating to the DDI between ATV and RIF is a major limitation to the use of ATV in patients who require treatment for TB.
- Trial name
- VirTUAL WP5 (NCT03923231)
- Testing
- Atazanavir 300mg/ Ritonavir 100 mg once daily, Atazanavir 250 mg / ritonavir 80 mg
- Where
- 4 sites in South Africa, Uganda
- Volunteers
- 32 people
- Sponsor
- University of Liverpool
Tuberculosis
Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa
TB kills most people with HIV in Africa. TB is out of control. Radically different approaches to deal with the disease is therefor needed. It is known that intensified case finding works in high HIV prevalence environments.
- Trial name
- XACT-2 (NCT03168945)
- Testing
- GeneXpert MTB/RIF, Smear microscopy
- Where
- South Africa
- Volunteers
- 608 people
- Sponsor
- University of Cape Town
Tuberculosis
A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried
There are four populations in Recombinant Mycobacterium tuberculosis Vaccine Freeze-dried (AEC/BC02) phase I clinical research. The clinical study adopt open research design.
- Trial name
- AEC/BC02 (NCT03026972)
- Testing
- Low dose adjuvant, High dose adjuvant, Low dose vaccine
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis, Adherence, Patient
Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes
Each year, 10.4 million patients are diagnosed with and 1.7 million people die from Tuberculosis (TB). Despite the availability of highly effective and accessible medications in the developing world where TB is endemic, the 6-18…
- Conditions
- Tuberculosis, Adherence, Patient, Adherence, Medication, Drug-resistant Tuberculosis
- Trial name
- NCT04119375
- Testing
- Keheala Mobile Health Platform and Behavioral Interventions, Social and Behavior Change Communication (SBCC), SMS Reminder
- Where
- Kenya
- Volunteers
- 16,146 people
- Sponsor
- Massachusetts Institute of Technology
Diabetes Mellitus, Pulmonary Tuberculosis
Pulmonary Tuberculosis Patients With Diabetes Mellitus
The purpose of this study is to evaluate the effect of enhanced glycemic monitoring of diabetes upon diabetes glycaemic control during tuberculosis treatment in tuberculosis- diabetes patients.
- Trial name
- TANDEM (NCT02106039)
- Testing
- intensive monitoring
- Where
- 3 sites in Indonesia, Peru and 1 more
- Volunteers
- 350 people
- Sponsor
- Universitas Padjadjaran
HIV/AIDS, Tuberculosis
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
The standard treatment for TB consists of rifampicin (RIF) as part of the regimen. However, due to drug-drug interactions (DDI), the bioavailability of PIs is greatly reduced when co-administered with RIF necessitating use of…
- Trial name
- DERIVE (NCT04121195)
- Testing
- Dose escalation
- Where
- Uganda
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.